News Under pressure, Novo lays out blockbuster launch plans Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.
News Telix to buy radiopharma rival ITM for $1.65bn upfront Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
News AZ's gMG drug Klygefa nears EU approval AstraZeneca's generalised myasthenia gravis (gMG) therapy Klygefa gets CHMP recommendation, alongside several other novel medicines.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
News CHMP backs Novo's haemophilia A drug Frehemgo Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
News MPs seek probe into UK-US pharma deal's impact on NHS The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.